Pfizer has paused its annual dividend increase for the first time in over a decade, maintaining a quarterly payout of $0.43 throughout 2026. This pause comes despite a strong 6.2% dividend yield and solid adjusted earnings coverage, reflecting caution amid declining sales of key products like Comirnaty and Paxlovid. Management remains confident in sustaining and eventually growing the dividend post-patent expirations, but investors should watch for signs of financial strain. Meanwhile, peers Merck and Bristol-Myers Squibb have continued raising their dividends, highlighting Pfizer's unique challenges.
Pfizer shares trade at USD 27.41 on Pluang as of Sep 18, 2026 22:21 WIB, showing a slight 0.81% decline in one day. The stock offers a strong dividend yield of 6.22%, which is notably higher than peers Merck at 2.31% and Bristol-Myers Squibb at 4.01%. Despite the dividend pause, investor interest remains high with 85% of Pluang orders to buy Pfizer shares at this time.
